ARVN
HEALTHCAREArvinas Inc
$10.26-0.35 (-3.30%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ARVN Today?
No stock-specific AI insight has been generated for ARVN yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$5.90$14.51
$10.26
Fundamentals
Market Cap$662M
P/E Ratio—
EPS$-1.14
Dividend Yield—
Dividend / Share—
ROE-0.2%
Profit Margin-0.3%
Debt / Equity—
Trading
Volume1.1M
Avg Volume (10D)—
Shares Outstanding64.5M
ARVN News
20 articles- Codexis (CDXS) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 7, 2026
- Earnings Preview: ProQR (PRQR) Q1 Earnings Expected to DeclineYahoo Finance·May 7, 2026
- Catalyst Monitor: Q2 2026 Outlook Report - Trial Initiations, Completions, Top-line Results, Regulatory Filings, PDUFA Dates, and Expected ApprovalsYahoo Finance·May 6, 2026
- Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026Yahoo Finance·May 5, 2026
- Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 MutationsYahoo Finance·May 4, 2026
- Protein degraders gain speed as Arvinas scores landmark approvalPharmavoice·May 4, 2026
- How The Arvinas (ARVN) Story Is Shifting With Vepdeg And ARV-102 MilestonesYahoo Finance·May 3, 2026
- Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast CancerYahoo Finance·May 1, 2026
- Arvinas’ ‘Protac’ breast cancer drug cleared by FDABiopharmadive·May 1, 2026
- How The Arvinas (ARVN) Story Is Evolving As 2026 Neurology Catalysts ApproachYahoo Finance·Apr 5, 2026
- Arvinas (ARVN) Moves 6.9% Higher: Will This Strength Last?Yahoo Finance·Apr 2, 2026
- Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 DaysYahoo Finance·Mar 18, 2026
- Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological DisordersYahoo Finance·Mar 11, 2026
- Arvinas Highlights Phase 1 Shift, 2026 Data Catalysts, and Vepdegestrant NDA at Barclays ConferenceMarketbeat·Mar 11, 2026
- Arvinas Teases Near-Term Phase 1 Data, Eyes New Vepdegestrant Partner at Leerink ConferenceMarketbeat·Mar 10, 2026
- How The Arvinas (ARVN) Narrative Is Evolving With New Leadership And Key 2026 Pipeline CatalystsYahoo Finance·Mar 6, 2026
- Arvinas Highlights Growing Phase 1 Pipeline, Near-Term Catalysts at TD Cowen Healthcare ConferenceMarketbeat·Mar 4, 2026
- Arvinas, Inc. (ARVN) Makes Significant Progress on Oncology and Neurology TrialsYahoo Finance·Mar 2, 2026
- Arvinas Inc (ARVN) Q4 2025 Earnings Call Highlights: Navigating Revenue Challenges with ...Yahoo Finance·Feb 24, 2026
- Arvinas (ARVN) Q4 2025 Earnings Call TranscriptMotley Fool·Feb 24, 2026
All 20 articles loaded
Price Data
Open$10.54
Previous Close$10.61
Day High$10.75
Day Low$10.24
52 Week High$14.51
52 Week Low$5.90
52-Week Range
$5.90$14.51
$10.26
Fundamentals
Market Cap$662M
P/E Ratio—
EPS$-1.14
Dividend Yield—
Dividend / Share—
ROE-0.2%
Profit Margin-0.3%
Debt / Equity—
Trading
Volume1.1M
Avg Volume (10D)—
Shares Outstanding64.5M
About Arvinas Inc
Arvinas, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development, and commercialization of therapies to break down disease-causing proteins. The company is headquartered in New Haven, Connecticut.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—